- PLN363.44m
- PLN518.45m
- PLN370.57m
Brief: Selvita Does Not Rule Out Share Issue For Breakthrough Transactions - CEO
Brief: Selvita Adopts Group Strategy For 2022-2025
Brief: Selvita FY Net Profit Down At 14.9 Mln Zlotys
Brief: Immagene And Selvita Announce Integrated Drug Discovery Cooperation
Brief: Selvita Signs 8.7 Mln Zloty Prelim Deal For Purchase Of Real Property In Krakow
Brief: Selvita Receives Purchase Order Of EUR 1.1 Million
Brief: Selvita Q3 Net Result Turns To Loss Of 1.0 Mln Zlotys
Brief: Selvita Unit Fidelta Signs Framework Deal With UK-Based Biotech Company
Brief: Selvita Q2 Net Result Turns To Loss Of 0.3 Mln Zlotys
Brief: Selvita Gets 3.3 Mln Zloty Subsidy From National Centre For R&D
Brief: Selvita Gets 4.7 Mln Zloty Grant On Using AI To Accelarate Drug Discovery Process
Brief: Selvita Unit Signs Framework Deal For 18.4 Mln Zlotys
Brief: Selvita Appoints Dean Bornilla As Vice President Of Sales, Head Of North America
Brief: Selvita Signs Deal With PORR For Construction Of R&D Centre
Brief: Selvita Q1 Net Profit Up At 9.4 Mln Zlotys
Brief: Selvita Says Total Non-Cash Expense From Incentive Programme Will Amount To PLN 75-88 Mln Spread Over 2021-2024
Brief: Selvita Obtains Status Of Research And Development Centre
Brief: Selvita Signs Loan Deals To Finance Fidelta Takeover
Brief: Selvita To Acquire Fidelta From Galapagos